Barclays’s AYTU BioPharma AYTU Stock Holding History

Barclays’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-50	Closed	-$108	–	5400
2026 Q2	$108	Buy	+50	New	+$118	﹤0.01%	5187
2025 Q4	–	Sell	-1	Closed	-$2	–	5246
2025 Q3	$2	Hold	1	–	–	﹤0.01%	5429
2025 Q2	$2	Hold	1	–	–	﹤0.01%	5182
2025 Q1	$1	Buy	+1	New	+$1	﹤0.01%	5223
2023 Q1	–	Hold	0	–	–	–	5084
2022 Q4	–	Hold	0	–	–	–	5267
2022 Q3	–	Hold	0	–	–	–	4781
2022 Q2	–	Hold	0	–	–	–	5018
2022 Q1	–	Hold	0	–	–	–	4943
2020 Q4	–	Sell	-53	Closed	-$12K	–	4867
2020 Q3	$12K	Sell	53 -10	-16%	-$2.57K	﹤0.01%	4972
2020 Q2	$18K	Buy	+63	New	+$19.1K	﹤0.01%	5218
2020 Q1	–	Hold	0	–	–	–	6131
2019 Q4	–	Hold	0	–	–	–	6342
2019 Q3	–	Hold	0	–	–	–	6703
2019 Q2	–	Hold	0	–	–	–	6935
2019 Q1	–	Hold	0	–	–	–	7005
2018 Q4	–	Hold	0	–	–	–	6930
2018 Q3	–	Hold	0	–	–	–	7112
2018 Q2	–	Hold	0	–	–	–	6960
2018 Q1	–	Hold	0	–	–	–	7048
2017 Q4	–	Hold	0	–	–	–	6917

Other funds holding AYTU

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Daytona Street Capital Saint Louis, Missouri $141M AUM 14.38% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Vision Financial Markets Stamford, Connecticut $131M AUM 8.71% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Barclays's AYTU Position: Q3 2026 in Review

Barclays sold out of AYTU BioPharma (AYTU) in Q3 2026, closing a stake of 50 shares — an estimated $108 sold.

Barclays first reported a position in AYTU in Q2 2020 and held it in 6 quarters. The position peaked at $18K in Q2 2020. 8 funds tracked by Wall St. Rank hold AYTU as of Q3 2026.

Barclays reported no remaining AYTU BioPharma position as of Q3 2026 after selling out during the quarter.
Barclays sold 50 AYTU BioPharma shares in Q3 2026, an estimated $108.
Barclays first reported a position in AYTU BioPharma in Q2 2020 and held it in 6 quarters.
Barclays's AYTU BioPharma position peaked at $18K in Q2 2020.
8 funds tracked by Wall St. Rank held AYTU BioPharma as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.